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http://www.infectagentscancer.com/content/7/1/36RESEARCH ARTICLE Open AccessToll-like receptor 3 in Epstein-Barr virus-associated
nasopharyngeal carcinomas: consistent
expression and cytotoxic effects of its synthetic
ligand poly(A:U) combined to a Smac-mimetic
Benjamin Vérillaud1,2*, Mélanie Gressette1, Yannis Morel3, Carine Paturel3, Philippe Herman2, Kwok Wai Lo4,
Sai Wah Tsao5, Michel Wassef6, Anne-Sophie Jimenez-Pailhes1 and Pierre Busson1Abstract
Background: Nasopharyngeal carcinomas (NPC) are consistently associated with the Epstein-Barr virus (EBV).
Though NPCs are more radiosensitive and chemosensitive than other tumors of the upper aero-digestive tract,
many therapeutic challenges remain. In a previous report, we have presented data supporting a possible
therapeutic strategy based on artificial TLR3 stimulation combined to the inhibition of the IAP protein family
(Inhibitor of Apoptosis Proteins). The present study was designed to progress towards practical applications of this
strategy pursuing 2 main objectives: 1) to formally demonstrate expression of the TLR3 protein by malignant NPC
cells; 2) to investigate the effect of poly(A:U) as a novel TLR3-agonist more specific than poly(I:C) which was used in
our previous study.
Methods: TLR3 expression was investigated in a series of NPC cell lines and clinical specimens by Western blot
analysis and immunohistochemistry, respectively. The effects on NPC cells growth of the TLR3 ligand poly(A:U) used
either alone or in combination with RMT5265, an IAP inhibitor based on Smac-mimicry, were assessed using MTT
assays and clonogenic assays.
Results: TLR3 was detected at a high level in all NPC cell lines and clinical specimens. Low concentrations of poly(A:
U) were applied to several types of NPC cells including cells from the C17 xenograft which for the first time have
been adapted to permanent propagation in vitro. As a single agent, poly(A:U) had no significant effects on cell
growth and cell survival. In contrast, dramatic effects were obtained when it was combined with the IAP inhibitor
RMT5265. These effects were obtained using concentrations as low as 0.5 μg/ml (poly(A:U)) and 50 nM (RMT5265).
Conclusion: These data confirm that TLR3 expression is a factor of vulnerability for NPC cells. They suggest that in
some specific pathological and pharmacological contexts, it might be worth to use Smac-mimetics at very low
doses, allowing a better management of secondary effects. In light of our observations, combined use of both types
of compounds should be considered for treatment of nasopharyngeal carcinomas.
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The TLRs are type-I transmembrane proteins which play
a key role in the detection of pathogens and in triggering
inflammation and immune response to microbial infec-
tions [1]. The stimulation of TLRs by their respective
ligands initiates well-characterized signaling cascades
that enhance cellular resistance against pathogens. TLRs
are expressed not only by immune cells, but also by vari-
ous cell types including normal and malignant epithelial
cells [2,3]. TLR3 is one category of TLR which interact
specifically with double-stranded RNA (dsRNA) of viral
origin. This binding leads in turn to MAPKs, NF-kB and
IRF-3 activation and to IFN-I induction via the adaptor
proteins TRIF and RIPK1 [1,4-6]. Activation of these
pathways results in the establishment of an anti-viral
phenotype. Many additional changes are induced by
TLR3 stimulation. Their overall consequences are
dependent on the intensity of the stimulation, on the cell
context and on concomitant extra-cellular signals. De-
pending on these conditions, they can result in apoptotic
cell death as well as enhancement of proliferation [7-10].
Nasopharyngeal carcinoma (NPC) is a malignant tumor
arising from the epithelial lining of the nasopharynx. Con-
sistently associated with the Epstein-Barr virus (EBV),
NPC is the third most frequent virus-associated malig-
nancy in humans [11,12]. Foci of high incidence (25 cases
per 100,000 individuals per year) are localized in South-
East Asia, especially in the Guangdong and Guangxi pro-
vinces of Southern China. There are also large areas of
intermediate incidence (3 to 8 cases) in South-East Asia
(Indonesia) and Northern Africa (Tunisia, Algeria and
Morocco) [12]. The multifactorial pathogenesis of NPC re-
lies on germ-line genetic susceptibility, acquired cellular
genetic and epigenetic alterations - especially under the in-
fluence of diet carcinogens - and EBV infection [12-14].
Although most viral genes are silent in NPC cells, some
are consistently expressed including those encoding the
nuclear protein EBNA1 (Epstein-Barr Nuclear Antigen 1),
two membrane proteins named LMP1 and LMP2 (Latent
Membrane Proteins 1 and 2) and the short untranslated
RNAs EBER1 and EBER2. Of the very large amounts of
EBERs produced and present in the nuclei of NPC cells,
some are exported in the cytoplasm and possibly in the
extra-cellular space [15]. Local inflammation is also sus-
pected to play a major role in NPC cell growth because of
the consistent presence of a massive lymphoid infiltrate in
the primary tumor and the intense local production of in-
flammatory cytokines [16,17]. Surprisingly, to our know-
ledge, there has been no report so far about the expression
of TLR3 in EBV-related nasopharyngeal carcinomas.
In a previous publication, we have reported that malig-
nant NPC cells are highly sensitive to a treatment combin-
ing a TLR3 artificial ligand (poly(I:C)) and a Smac-mimetic,
RMT5265 which inhibits several proteins of the IAP family(Inhibition of Apoptosis Proteins; namely c-IAP1, c-IAP2
and XIAP) [18]. However poly(I:C) is not strictly specific
of TLR3; it interacts with other cellular receptors of
double-strand RNAs, especially RIG-I and MDA5 [19].
This lack of specificity might result in undesirable side-
effects when used in humans. Therefore, we undertook to
investigate the anti-tumoral effects of poly(A:U) in the
same experimental context. Poly(A:U) is a TLR3 agonist
which does not interact with RIG-I and MDA5 and which
is believed to be better tolerated in medical use [19].
The aims of the present study were to confirm the ex-
pression of the TLR3 protein in NPC cells and to assess
their sensitivity to poly(A:U) as a single agent and in
combination with RMT5265. We report that TLR3 is
consistently detected in all investigated NPC cell lines
and specimens. We also show that various NPC cell lines
are exquisitely sensitive to this combined treatment in
both high density cultures and clonogenic assays.
Materials and methods
Xenografts and cell lines
The following NPC cell lines were used throughout the
study: C666-1, C15, C17, C18 (EBV positive cell lines),
CNE1 and HONE1 (EBV negative cell lines). A panel of
non-NPC epithelial malignant and non malignant cell
lines was used as control for TLR3 expression assess-
ment: FaDu and SQ20B (head and neck squamous cell
carcinoma, HNSCC), HeLa (cervical carcinoma), A431
(vulvar squamous carcinoma), A549 (non-small cell lung
cancer), C33 and CaSki (cervical carcinomas), NP69 and
NP460 (derived from non-malignant nasopharyngeal epi-
thelial cells immortalized by SV-40 infection and stable
transfection of the gene encoding the telomerase cata-
lytic subunit hTert, respectively) [20-26]. The non-
malignant nasopharyngeal NP69 cell line was also used
as a control for proliferation assays.
C666-1 cells are EBV-positive NPC cells which have
been grown for a long time either as xenografted tumors
or in vitro cultures [27]. Through this study, we used
C666-1 cells stably transfected with the luciferase 1 gene
which were kindly provided by Dr Fei-Fei Liu (university
of Toronto, Ontario, Canada) [27,28]. These cells retain
the EBV genome and intense expression of the EBER
viral non-coding RNAs (see the result section). Because
the luciferase gene is very stable in these cells both
in vitro and in vivo, it allows in vivo imaging of the
xenografted tumors. Therefore, we chose to use them
from the beginning in anticipation of future in vivo stud-
ies about the effects of TLR3 agonists on NPC cells.
C666-1 cells were routinely propagated in vitro using
RPMI 1640 medium (Gibco-Invitrogen, Carlsbad, CA)
supplemented with 25 mM HEPES and 7.5% fetal calf
serum (FCS), in plastic flasks coated with collagen I
(Biocoat; Becton-Dickinson, Franklin Lakes, NJ). C15,
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gated by subcutaneous passages into nude mice [29]. For
a long time, it has not been possible to derive long-term
in vitro cultures from any of these three xenografts.
However, we recently adapted C17 cells to permanent
in vitro propagation using a protocol inspired from Liu
et al. [30]. Briefly, C17 xenografted tumors were minced
and treated with type II collagenase for cell dispersion as
previously reported [16]. Cells were then plated on a
non-irradiated feeder layer of Normal Human Dermal
Fibroblasts (NHDF; Promocell, Heidelberg, Germany)
and grown in RPMI 1640 medium (Gibco-Invitrogen)
supplemented with 25 mM HEPES, 7.5% fetal calf serum
(FCS), and 7 μmol/L of the Rho kinases I and II inhibitor
Y-27632 (Y-27632; Enzo Life Sciences, Lausen, Switzer-
land) [31]. Feeder cells became rapidly senescent. Most
of them were already eliminated beyond the third
in vitro passage. For cytological analysis, C17 cells were
stained with hematoxilin and eosin safran (HES) after
cytospin preparation. Detection of the EBERs by in situ
hybridization on C666-1, HeLa, and C17 cell pellets was
performed using the INFORM EBER Probe (Ref 800–
2842) and the ISH iVIEW Blue Detection Kit (Ref 800–
092) from Ventana-Roche (Tucson, AZ). EBV-negative
cell lines CNE1 and HONE1 were grown in RPMI 1640
medium (Gibco-Invitrogen) supplemented with 5% FCS
[32,33]. NP69 cells were grown in keratinocyte serum-
free medium (Gibco) supplemented with 10% FCS.
Clinical specimens and immunohistochemistry
Biopsies were obtained from 10 patients referred to the
Lariboisière hospital (Paris, France). All patients had non-
keratinizing undifferentiated (or type III) NPC according
to the WHO classification (2005). Biopsies were fixed in
formaldehyde and paraffin-embedded. Tissue sections
were microwaved at 98°C for 30 minutes in citrate buffer
(10 mM, pH 7.3) and then incubated with an antihuman
TLR3 mouse monoclonal antibody (40 F9.6, Innate
Pharma, Marseille). Binding of the primary antibody was
detected with the CSA II kit from Dako (based on a tyra-
mide amplification system; DakoCytomation, Glostrup,
Denmark). C666-1 and NP69 cell pellets embedded in par-
affin were used for positive and negative control of TLR3
immunostaining. All the clinical samples were obtained
and processed according to the guidelines of Lariboisière
hospital institutional review board. requiring written
informed consent from patients for publication.
Treatments of cells with pharmacological reagents
The polycyclic C2-symmetric (40 carbon atoms) com-
pound RMT5265 mimics the three-dimensional structure
of the N-terminal tetrapetide of Smac/Diablo (second
mitochondria–derived activator of caspases) [34]. This
compound was kindly provided by Xiaodong Wang,Dallas. It was dissolved in DMSO. The TLR3 agonists -
poly(I:C) and poly(A:U) - were obtained from InvivoGen
(San Diego, CA). Cisplatinum was purchased from Sigma
Aldrich (St. Quentin Fallavier, France).
Cell growth and viability assays
Cell viability was determined in a short-term assay based
on the reduction of MTT (CNE1, HONE1, NP69, C17)
or WST (a soluble form of MTT; C666-1). MTT and
WST were purchased from Sigma Aldrich. For this assay,
cells were seeded in 96-well plates at a density of 2 x 103
(CNE1, HONE1, NP69) or 3 × 104 (C666-1, C17) cells
per well. The MTT/WST reaction was performed after
72 hours of culture. The absorbance (Optical Density
(OD)) was measured at 550 nm and 450 nm for MTT
and WST assays, respectively. The percentage of inhib-
ition was determined based on the difference of OD be-
tween treated and untreated cells, after subtraction of
the optical background.
Alternatively, in vitro growth assays at low density were
performed to evaluate the clonogenic potential of NPC
cells. HONE1, CNE1 and NP69 cells were plated in six-
well plates (5x102 cells per well) and treated at day 1 with
RMT5265 and/or poly(I:C) / poly(A:U). After 2 weeks of
culture, cell colonies were stained with a solution of Crys-
tal Violet (Sigma Aldrich) in methanol. The clonal growth
of C666-1 NPC cells was assessed using a feeder layer of
Normal Human Dermal Fibroblasts (NHDF, Promocell).
The first day of clonogenic assay, NHDF were plated in
six-well plates (1.5x105 per well). 24 hours later, they
were irradiated (40 Gy) and C666-1 NPC cells were
added at a density of 5x103 cells per well. After 24 hours,
once the epithelial cells had firmly adhered to the plate,
RMT5265 and/or poly(I:C) / poly(A:U) were added to the
culture medium. Replacement by fresh medium was done
once a week. After 2 to 4 weeks of culture, cell colonies
were stained with a solution of Rhodanile Blue (Sigma
Aldrich) in ethanol. Dried plates were then scanned and
digitized to allow optical magnification and precise
counting of cell colonies.
We used the Bliss additivism model to quantify the
level of synergy in our drug-combination experiments
[35]. The predictive Bliss additive effect C of two single
compounds with effects A and B is: C = A + B - A·B.
The excess over Bliss additivism (EOBA) was calculated
by subtracting the predicted Bliss additive effect from
the experimentally observed inhibition. It is expressed as
a percentage, and represents the excess of inhibition over
the predicted response that was obtained when 2 com-
pounds were used in combination.
Assessment of PARP cleavage
Apoptosis was evaluated by the detection of the cleavage
of poly(ADP-ribose)polymerase (PARP) by Western blot
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paragraph).Cell protein extraction and western blot analysis
Proteins from cultured cells or xenografts were extracted
by lysis in RIPA buffer (50 mM Tris, 150 mM NaCl,
5 mM EDTA, 0.5% sodium deoxycholic acid, 0.5% NP-
40, 0.1% SDS) supplemented with a protease inhibitor
cocktail (Complete; Roche Molecular, Neuilly sur Seine,
France). They were separated by SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes (Immobi-
lon, Millipore, Billerica, CA) by electroblot at 4°C for
90 minutes at 90 V or overnight at 45 V. The antibodies
used for Western blot analysis were mouse monoclonal
antibodies directed against the human TLR3 (clone
512505, ref. MAB1487, R&D Systems), PARP (C-2-10,
ref. 53643; Santa Cruz Biotechnology), β-Actin (AC-74;
Sigma Aldrich) and α-Tubulin (B-5-1-2; Sigma Aldrich).
Blotted membranes were incubated with a secondary
peroxidase-conjugated antibody, and chemiluminescent
detection was done using the Immobilon Western
Chemiluminescent HRP Substrate (Millipore, Billerica,
CA). Specific protein bands were quantified using Image-
Quant TL software (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) when the acquisition was performed
with ImageQuant LAS 4000 mini biomolecular imager
(GE Healthcare Bio-Sciences AB), and a GS-710 cali-
brated imaging densitometer with Quantity One software
(Biorad, Marnes la Coquette, France) when detection was
performed on chemiluminescence films.Figure 1 TLR3 is highly expressed in NPC cell lines and xenografts. W
C666-1, C18, C17 and C15 xenografts/cell lines (A), and in EBV-negative HO
TLR3 in NPC cells, its expression was simultaneously assessed in C666-1, in
and FaDu, and in a panel of non malignant and malignant epithelial cell-lin
nasopharyngeal cell lines), HeLa, C33 and CaSki (cervical carcinoma), SW613
squamous carcinoma) (C). The same blotted membranes were stained withResults
TLR3 is constitutively expressed by NPC cells
We investigated expression of TLR3 by western blot ana-
lysis in cell extracts from EBV-positive NPC tumor cells
propagated in vitro (C666-1) or as xenografts (C15, C17,
C18, C666-1) and in EBV-negative HONE1 and CNE1 cell
lines comparatively to a panel of malignant and non ma
lignant epithelial cell lines. Malignant cell lines were
derived from HNSCC (SQ20B, FaDu), colon carcinoma
(SW613), cervical carcinoma (HeLa, C33, CaSki), vulvar
squamous carcinoma (A431), and non-small cell lung
cancer (A549). NP69 and NP460 are immortalized non-
tumorigenic cell lines derived from human nasopharyngeal
epithelial cells. As shown in Figure 1A and 1B, TLR3
was consistently detected in NPC cell lines and xeno-
grafts, either EBV-positive (Figure 1A) or EBV-negative
(Figure 1B). Its abundance was at a maximal level in
extracts from NPC cells and xenografts followed by
extracts from HNSCC cells (SQ20B and FaDu) ; in con-
trast, TLR3 was undetectable or at a low level in extracts
from other carcinoma cells or from non-tumorigenic
nasopharyngeal epithelial cells (Figure 1C). Modest levels
of TLR3 were detected in CaSki and A431 malignant cell-
lines, and in the non malignant nasopharyngeal cell-line
NP460. On the other hand, we analyzed the in situ expres-
sion of TLR3 by immunohistochemistry in ten biopsies
from primary NPC tumors. Positive and negative controls
were C666-1 and NP69 cell pellets, respectively
(Figure 2A). The TLR3 protein was consistently detected
in NPC biopsies. In six out of ten specimens, most malig-
nant cells were positive. In contrast, TLR3 staining wasestern blot analysis reveals intense expression of TLR3 in EBV-positive
NE1 and CNE1 NPC cell lines (B). To better characterize the status of
the non NPC head and neck squamous cell carcinoma cell lines SQ20B
es, namely NP69 and NP460 (non tumorigenic immortalized
(colon carcinoma), A549 (non-small cell lung cancer), and A431 (vulvar
anti-actin for protein loading controls.
Figure 2 TLR3 is consistently detected by immunohistochemistry on tissue sections from NPC biopsies. (A) C666-1 and NP69 cell pellets
were used as positive and negative controls for TLR3 immunostaining, respectively; note the strong juxtanuclear staining in C666-1 cells
(suggestive of endosomal TLR3 localization) and the low level of staining in NP69 cells, consistent with western blot data displayed in figure 1C.
(B,C) NPC biopsy sections (B = patient#6; C = patient#8) were stained with hematoxilin and eosin safran (HES), or immunostained with antihuman
TLR3 antibody (40 F9.6, Innate Pharma, Marseille). TLR3 was detected in all biopsies in a substantial fraction of cells, although with heterogeneous
levels of intensity.
Table 1 Detection of the TLR3 protein by
immunohistochemistry on tissue sections from NPC
biopsies
Patient
N°
Origin Gender/
age
Clinical
stage
TLR3 staining
Distribution Intensity
1 Tunisia M/48 T4N3bM1 Homogeneous Faint
2 Romania F/34 T2bN0M0 Heterogeneous Moderate
3 Cameroon M/62 T4N2M0 Heterogeneous Moderate
4 France M/63 T4N0Mx Homogeneous Strong
5 France M/62 T3N2M0 Heterogeneous Strong
6 Portugal F/84 T4N2M0 Heterogeneous Strong
7 Algeria M/40 T4N2M0 Homogeneous Faint
8 Turkey M/57 T1N0M0 Homogeneous Moderate
9 China F/31 T4N0M0 Homogeneous Moderate
10 France M/48 T1N2M0 Homogeneous Faint
All specimens were of the non-keratinizing undifferentiated histologic subtype
of the WHO classification (2005).
Images for cases 6 and 8 are displayed in Figure 2.
M0 indicates absence of extranodal metastases; M1, presence of extranodal
metastases at the time of diagnosis; Mx, no assessment of distant metastases.
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lymphocytes. In the remaining four specimens, only a frac-
tion of malignant cells scored positive, again with absence
of staining or very low staining of infiltrating cells
(Figure 2B, 2C and Table 1).
The TLR3 agonist poly(A:U) and the Smac mimetic
RMT5265 have synergistic cytotoxic effects on NPC cells
In a previous study, we reported the antiproliferative
effects of a combination of the synthetic TLR3 agonist
poly(I:C) and the Smac-mimetic RMT5265 on various
types of malignant epithelial cells including NPC cells
[36]. However, as already mentioned, poly(I:C) is known
to stimulate not only TLR3, but also MDA5 and RIG-I,
two cytoplasmic receptors of dsRNAs [19]. This is not
the case for another TLR3 agonist, poly(A:U) [19].
Therefore, both TLR3 agonists were used, either alone or
in combination with a Smac-mimetic (RMT5265), to as-
sess their cytotoxic effects on NPC cells. Target cells
were NPC cell lines (C666-1, HONE1 and CNE1) and
non-malignant nasopharyngeal epithelial cells (NP69).
They were treated for 72 hours with pharmaceutical
agents used at low concentrations, ie less than 1 μg/mL
for TLR3 agonists and 50 nM for RMT5265, and cell
viability was subsequently assessed with WST/MTT
assays. Poly(A:U) and poly(I:C) had similar cytotoxic
effects on NPC cells when used in combination with the
Smac-mimetic RMT5265 (Figure 3A). For example, inC666-1 cells, concentrations of RMT5265 as low as 5nM
combined to poly(I:C) or poly(A:U) (0.5 μg/ml) were suf-
ficient to achieve major cytotoxic effects. The combin-
ation of poly(A:U) with cisplatinum, namely the most
widely used pharmacological agent in NPC treatment,
revealed by contrast no more than an additive effect
(data not shown). The TLR3 agonist/Smac-mimetic
Figure 3 Poly(A:U) and RMT5265 have cooperative cytotoxic effects on NPC cells. (A) MTT cell-growth assay for NPC cells and
non-tumorigenic nasopharyngeal epithelial cells treated with poly(I:C) or poly(A:U) (0.5 μg/mL for C666-1 and HONE1, 1 μg/mL for CNE1 and
NP69) used either alone or in combination with a Smac-mimetic RMT5265 (5 nM for C666-1, 50 nM for CNE1, HONE1 and NP69). Poly(A:U) is
known to have greater specificity for TLR3 than poly(I:C) which also stimulates the MDA5 and RIG-I receptors [19]. Despite this more restricted
action, poly(A:U) combined with RMT5265 had cytotoxic effects on NPC cells almost equivalent to poly(I:C) and no effect on NP69 cells. Excess
over Bliss additivism was calculated as indicated in the Materials and Methods section. The results are given as mean +/− SD. (B) Detection of
PARP cleavage by Western blot analysis. Proteins were extracted after 24 h of culture from NPC cells treated with poly(I:C) or poly(A:U) used either
alone or in combination with RMT5265. The drugs were used at the same concentrations as for the WST/MTT assays. 40 μg of protein extracts
were loaded on PAGE gels. The blotted membranes stained with anti-PARP antibodies were also stained with anti-tubulin for protein loading
control. No massive PARP cleavage was observed in any experimental condition. However the most abundant cleaved products were seen
when poly(A:U) or poly(I:C) were combined with RMT5265.
Vérillaud et al. Infectious Agents and Cancer 2012, 7:36 Page 6 of 10
http://www.infectagentscancer.com/content/7/1/36combination had no effect on NP69 non malignant naso-
pharyngeal epithelial cells (Figure 3A). To evaluate the
contribution of apoptosis to the cytotoxic effects of the
TLR3 agonists/Smac-mimetic combinations, PARP cleav-
age was assessed in treated cells. Malignant cells were
exposed for 24 hours to poly(I:C)/poly(A:U) and/or
RMT5265 at concentrations similar to those used for sur-
vival assays. No massive PARP cleavage was observed in
any experimental condition, suggesting that the cytotoxic
effects of treatment by single agents or combinations of
two agents were only partially accounted for by apoptosis
(Figure 3B). Nevertheless, a PARP cleavage of low inten-
sity was detected in NPC cells treated with RMT5265 as
a single agent. This cleavage was substantially enhanced
when RMT5265 was combined to poly(A:U) or poly(I:C).Additional investigations were subsequently performed
on C17 cells. These EBV-positive NPC cells which have
been propagated as xenografts for many years were re-
cently adapted to permanent in vitro propagation in our
laboratory using a protocol described by Liu et al. (see
Materials and Methods sections) [30]. This protocol
which is proposed for primary cultures of a wide range
of epithelial cell types, either malignant or non-malig-
nant, has two main characteristic features: use of a feeder
layer of non-transformed fibroblasts and addition of a
Rho kinase inhibitor (Y-27632) to the culture medium.
After the third in vitro passage of the C17 cells, we
observed that the feeder layer was no longer required. In
contrast, any attempt to withdraw the Rho kinase inhibi-
tor resulted in a very rapid growth arrest (Figure 4A).
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croscopy is displayed in Figure 4B. The kinship of C17
cells propagated in vitro with C17 xenograft was con-
firmed by genotyping of HLA-A (HLA-A*02, *26) and
HLA-B (HLA-B*44, *51) alleles. The EBV status of C17
cells propagated in vitro was assessed by EBERs
hybridization on C17 cell pellets embedded in paraffin.
HeLa and C666-1 cell pellets were used as negative and
positive control, respectively. EBERs hybridization was
positive, confirming that C17 cells retained the EBV gen-
ome when they were propagated in vitro (Figure 4C). Like
all other NPC cells, C17 cells propagated in the presence
of Y-27633 were exquisitely sensitive to the combination
of TLR3 agonists with RMT5265 as shown by MTT assays
(Figure 4D).
Finally, we assessed the effects of the poly(A:U)/
RMT5265 combination on NPC cells clonogenic
growth: concordantly with previous results, this thera-
peutic combination strongly inhibited the clonal growth
of NPC cells, and had no effect on NP69 cells
(Figure 5).Figure 4 In vitro propagation of C17 cells and sensitivity to TLR3 ago
xenografted tumors and their propagation in vitro was made possible for th
culture medium. (A) MTT assay was used to determine the growth characte
inhibitor Y-27632 or not. (B) Morphological aspect of C17 cells propagated
of mitosis (black arrowheads) and apoptosis (white arrows). C17 cells were
positive EBV status of C17 cells was confirmed by EBERs hybridization, using
respectively. (D) MTT cell-growth assay on C17 cells treated with poly(I:C) o
Smac-mimetic RMT5265 (200 nM). Excess over Bliss additivism (EOBA) confi
mean +/− SD.Discussion
TLR3 overexpression has been reported in a number of
human malignancies, such as melanoma, breast cancer,
clear cell carcinoma, neuroblastoma, or head and neck
squamous cell cancer [2,37-40]. To our knowledge, this
is the first report of TLR3 expression in EBV-related
NPC. The fact that TLR3 is strongly expressed by malig-
nant NPC cells in vitro suggests that its expression is
not a consequence of intra and peritumoral inflamma-
tion but is a constitutive feature of NPC cell pheno-
type. However, its expression is probably modulated
by the tumor microenvironment. Investigations on tis-
sue sections show that, in some fresh tumors in situ,
TLR3 expression is homogeneous through all malig-
nant cells whereas in some other tumors it is
restricted to a subset of malignant NPC cells. Add-
itional investigations will be required to determine
whether TLR3-positive and TLR3-negative cells have
distinct features in terms of proliferation and cell cyc-
ling, adaptation to hypoxia or influence of immune in-
filtrating cells.nists combined to RMT5265. C17 NPC cells were dispersed from
e first time by adding a Rho kinase inhibitor (Y-27632) to the
ristics of C17 cells cultured in media containing the Rho kinase
in vitro under optical microscopy. The aspect of some cells is evocative
stained with HES after cytospin preparation (passage 5 in vitro). (C) The
HeLa and C666-1 cell pellets as negative and positive control,
r poly(A:U) (0.25 μg/mL) used either alone or in combination with the
rms the synergic effects of these combinations. The results are given as
Figure 5 Synergistic inhibition of NPC cells clonogenic growth by combination of poly(A:U) with a Smac-mimetic. NPC cells and NP69
cells were treated with poly(A:U) (0.25 μg/mL for C666-1, 0.5 μg/mL for HONE1, 1 μg/mL for CNE1 and NP69) used either alone or in combination
with RMT5265 (5 nM for C666-1 and HONE1, 30 nM for CNE1 and NP69). A feeder of irradiated Normal Human Dermal Fibroblasts (NHDF) was
used for C666-1 clonogenic assays as described in the Materials and Methods section. (A) A representative aspect of the results of the clonogenic
assays is displayed in the upper panel. (B) The percentage of inhibition was calculated based on the number of colonies, and the excess over Bliss
additivism (EOBA) confirmed the synergic effects of the therapeutic combinations on NPC cells. The results are given as mean +/− SD.
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cells suggests that it plays a role in NPC tumour growth.
There are several potential natural endogenous ligands
for TLR3 in NPC tumors. EBER RNAs are the first can-
didates. These viral non-coding RNAs are extremely
abundant in NPC cells as in other types of latently EBV-
infected cells; most of them are contained in the nucleus
but a fraction of them can diffuse to the cytoplasm and
the extra-cellular medium. In EBV-transformed B-lym-
phocytes, these extra-nuclear EBERs have been shown to
bind TLR3 and to induce the production of inflamma-
tory cytokines [41]. In NPC cells, the EBERs are known
to induce the production of Insulin Growth Factor 1
(IGF1) which is itself an autocrine growth factor for
NPC cells [42]. There is a suspicion that this effect is
mediated, at least in part, by TLR3 [43]. That point will
deserve further investigations. Beside the EBER RNAs,
there are other potential ligands of TLR3 in tumor tis-
sues. Messenger RNAs released by necrotic cells are
known to bind and stimulate TLR3 probably as a conse-
quence of the formation of secondary structures contain-
ing double strand domains [44,45]. The influence of
necrotic messenger RNAs on NPC cell growth will also
deserve investigations.
In an apparent paradox, several in vitro studies have
underlined the potential of TLR3 as a therapeutic target
for various types of human malignant cells [2,37,46,47].
However, the cytotoxic effects of TLR3 stimulation in
the absence of another pharmacological agent, usually
require extremely high concentrations of agonists, for
example 10 to 100 μg/ml of poly(I:C). More recently, weand others have shown that it is possible to achieve a
cytotoxic effect with much lower concentrations of poly
(I:C) (in the range of 1 μg/ml) provided that the TLR3
agonist is combined with a Smac-mimetic [18,36,48]. Re-
cently, the molecular rationale of this combination has
been partially understood. Feoktistova et al. have
described the “Ripoptosome”, an intracellular signaling
platform containing caspase 8, caspase-10, RIPK1,
FADD, and FLIP isoforms (short isoform FLIP-S or long
isoform FLIP-L) that regulates cell death by apoptosis or
programmed necrosis (necroptosis) in response to TLR3
ligands [48,49]. In this model, the c-IAPs prevent the for-
mation and stabilization of the ripoptosome by ubiquiti-
nation and subsequent proteasomal degradation of a
fraction of RIPK1 whereas FLIP-L inhibits the entry of
RIPK1 and FADD into the ripoptosome following TLR3
stimulation. According to this model, the inhibition of
the c-IAPs is believed to promote TLR3-induced cell
death, either by caspase 8-mediated apoptosis or by
RIPK1-RIPK3-mediated necroptosis, depending on the
pre-existing levels of FLIP-S and FLIP-L.
In this study, we report that the combination of the
poly(A:U) with the Smac-mimetic is as efficient as the
combination involving poly(I:C). We also demonstrate
that extremely low concentrations of both compounds -
below 1 μg/mL for poly(A:U) and 50 nM for RMT5265 -
are sufficient to achieve a significant cytotoxic effect.
These data have important practical implications because
poly(A:U) has distinctive characteristics which might be
better suited for some patients than poly(I:C). It has a
higher specificity for TLR3 and is believed to induce less
Vérillaud et al. Infectious Agents and Cancer 2012, 7:36 Page 9 of 10
http://www.infectagentscancer.com/content/7/1/36systemic inflammatory effects [19]. It has already been
evaluated in association with standard treatment in 5
phase III clinical trials [50-54]. Salaun et al. have reported
that adjuvant treatment with poly(A:U) was associated
with a significant decrease in the risk of metastatic relapse
in TLR3 positive breast cancers [37]. In summary our data
might have important implications not only for NPC treat-
ment but also for other malignancies.
Conclusion
We report that TLR3 is consistently expressed by malig-
nant cells in NPC cell lines and clinical specimens. Low
concentrations of the specific TLR3 agonist poly(A:U)
combined to low concentrations of an IAP inhibitor have
cytotoxic effects on NPC cells. These data confirm that
TLR3 expression is a factor of vulnerability for NPC cells
as it is the case for other head and neck carcinomas
[40,55]. Additional investigations will be required to
understand which type of growth advantage is associated
with the consistent expression of TLR3 by NPC cells.
Abbreviations
NPC: Nasopharyngeal carcinoma; HNSCC: Head and neck squamous cell
carcinoma; TLR3: Toll-like receptor 3; RIG-I: Retinoic acid inducible gene I;
PKR: Protein kinase R; Smac: Second mitochondria–derived activator of
caspases; c-IAP: Cellular inhibitor of apoptosis Xprotein; XIAP: X-linked
inhibitor of apoptosis protein; FLIP-L: Long isoform of the FLICE-like inhibitory
protein.
Competing interests
YM and CP are employed by Innate Pharma, a company developing a TLR3
agonist. All other authors certify that they have no conflict of interest.
Authors’ contribution
BV and MG have performed most of the experiments. ASJP carried out NPC
xenografts and shared her expertise in cell culture and Western blot analysis.
YM and CP contributed the antihuman TLR3 mouse monoclonal antibody
(40 F9.6, Innate Pharma, Marseille) for detection of TLR3 by
immunohistochemistry. MW and PH have provided pathological samples for
immunohistochemistry. MW, BV and PB have analyzed and interpreted
stained tissue sections. KWL has provided the C666-1 cell line. SWT has
provided the NP460 and NP69 cell lines. BV and PB designed the study, and
drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a grant from the “Fondation Gustave Roussy”
(Research on Head and Neck tumors, 2011) and the Ligue Nationale contre
le Cancer (comité du Val de Marne). BV was the recipient of a fellowship
from the Institut National du Cancer (FOR – 2010-INCa_3113) and from the
APHP-CNRS (RAFCNR11). We thank Dr Fei-Fei Liu (university of Toronto,
Ontario, Canada) and Pr Xiaodong Wang (university of Texas, Dallas, USA) for
generous gift of the C666-1 cells [27,28] and RMT5265 compound [34]
respectively.
Author details
1CNRS-UMR 8126, Institut de Cancérologie Gustave Roussy, University
Paris-Sud 11, 39 rue Camille Desmoulins, 94805, Villejuif cedex, France.
2Department of Head and Neck surgery, Lariboisière Hospital, AP-HP,
University Paris-Diderot Paris 7, Paris, France. 3Innate Pharma, Marseille,
France. 4Department of Anatomical and Cellular Pathology, State Key
Laboratory in Oncology in South China, Prince of Wales Hospital, The
Chinese University of Hong Kong, Ma Liu Shui, Hong Kong. 5Department of
Anatomy, the University of Hong Kong, Pok Fu Lam, Hong Kong.
6Department of Pathology, Lariboisière Hospital, AP-HP, University
Paris-Diderot Paris 7, Paris, France.Received: 18 September 2012 Accepted: 20 November 2012
Published: 3 December 2012References
1. Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of
innate immunity with Toll-like receptor agonists and antagonists.
Nat Med 2007, 13(5):552–559.
2. Salaun B, Romero P, Lebecque S: Toll-like receptors' two-edged sword:
when immunity meets apoptosis. Eur J Immunol 2007, 37(12):3311–3318.
3. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H: TLR signaling by tumor
and immune cells: a double-edged sword. Oncogene 2008, 27(2):218–224.
4. Han KJ, Su X, Xu LG, Bin LH, Zhang J, Shu HB: Mechanisms of the
TRIF-induced interferon-stimulated response element and
NF-kappaB activation and apoptosis pathways. J Biol Chem 2004,
279(15):15652–15661.
5. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M,
Tschopp J: RIP1 is an essential mediator of Toll-like receptor 3-induced
NF-kappa B activation. Nat Immunol 2004, 5(5):503–507.
6. Brown J, Wang H, Hajishengallis GN, Martin M: TLR-signaling networks: an
integration of adaptor molecules, kinases, and cross-talk. J Dent Res 2011,
90(4):417–427.
7. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T: TLR3 can directly
trigger apoptosis in human cancer cells. J Immunol 2006,
176(8):4894–4901.
8. Lin Q, Wang L, Lin Y, Liu X, Ren X, Wen S, Du X, Lu T, Su SY, Yang X, et al:
Toll-Like Receptor 3 Ligand Polyinosinic: Polycytidylic Acid Promotes
Wound Healing in Human and Murine Skin. J Invest Dermatol 2012,
132(8):2085–2092.
9. Bernard JJ, Cowing-Zitron C, Nakatsuji T, Muehleisen B, Muto J, Borkowski
AW, Martinez L, Greidinger EL, Yu BD, Gallo RL: Ultraviolet radiation
damages self noncoding RNA and is detected by TLR3. Nat Med 2012,
doi:10.1038/nm.2861.
10. Matijevic T, Pavelic J: Toll-like receptors: cost or benefit for cancer?
Curr Pharm Des 2010, 16(9):1081–1090.
11. Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal
carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1765–1777.
12. Feng B: Descriptive, Environmental and Genetic Epidemiology of
Nasopharyngeal Carcinoma. In Nasopharyngeal Carcinoma: Keys for
Translational Medicine and Biology. Edited by Busson P. New York:
Austin, Tex :Landes Bioscience / Springer; 2012.
13. Gourzones C: Epstein-Barr Virus and the Pathogenesis of Nasopharyngeal
Carcinomas. In Nasopharyngeal Carcinoma: Keys for Translational Medicine
and Biology. Edited by Busson P. New York: Austin, Tex :Landes Bioscience /
Springer; 2012.
14. Lo KW: Acquired Genetic and Epigenetic Alterations in Nasopharyngeal
Carcinoma. In Nasopharyngeal Carcinoma: Keys for Translational Medicine
and Biology. Edited by Busson P. New York: Austin, Tex :Landes Bioscience /
Springer; 2012.
15. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K: EB virus-encoded
RNAs are recognized by RIG-I and activate signaling to induce type I IFN.
EMBO J 2006, 25(18):4207–4214.
16. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S,
Ferradini L, Bosq J, Tursz T, Busson P: Control of apoptosis in Epstein Barr
virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95
and CD40 stimulation. Cancer Res 1999, 59(4):924–930.
17. Tang KF, Tan SY, Chan SH, Chong SM, Loh KS, Tan LK, Hu H: A distinct
expression of CC chemokines by macrophages in nasopharyngeal
carcinoma: implication for the intense tumor infiltration by T
lymphocytes and macrophages. Hum Pathol 2001, 32(1):42–49.
18. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, Ripoche H,
Khabir A, Tsao SW, Bosq J, Lo KW, et al: Recurrent overexpression of
c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in
resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 2008,
10(11):1183–1194.
19. Perrot I, Deauvieau F, Massacrier C, Hughes N, Garrone P, Durand I, Demaria
O, Viaud N, Gauthier L, Blery M, et al: TLR3 and Rig-like receptor on
myeloid dendritic cells and Rig-like receptor on human NK cells
are both mandatory for production of IFN-gamma in response to
double-stranded RNA. J Immunol 2010, 185(4):2080–2088.
20. Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW,
Lo AK, Wong YC, et al: Establishment of two immortalized
Vérillaud et al. Infectious Agents and Cancer 2012, 7:36 Page 10 of 10
http://www.infectagentscancer.com/content/7/1/36nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7
viral oncogenes. Biochim Biophys Acta 2002, 1590(1–3):150–158.
21. Rangan SR: A new human cell line (FaDu) from a hypopharyngeal
carcinoma. Cancer 1972, 29(1):117–121.
22. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J, Ervin
TJ: Radiation-resistant and repair-proficient human tumor cells may be
associated with radiotherapy failure in head- and neck-cancer patients.
Proc Natl Acad Sci USA 1986, 83(8):2684–2688.
23. Scherer WF, Syverton JT, Gey GO: Studies on the propagation in vitro of
poliomyelitis viruses. IV. Viral multiplication in a stable strain of human
malignant epithelial cells (strain HeLa) derived from an epidermoid
carcinoma of the cervix. J Exp Med 1953, 97(5):695–710.
24. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G: A continuous
tumor-cell line from a human lung carcinoma with properties of type II
alveolar epithelial cells. Int J Cancer 1976, 17(1):62–70.
25. Auersperg N: Long-term cultivation of hypodiploid human tumor cells.
J Natl Cancer Inst 1964, 32:135–163.
26. Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF:
Tumor antigen and human chorionic gonadotropin in CaSki cells: a new
epidermoid cervical cancer cell line. Science 1977, 196(4297):1456–1458.
27. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney
BM, Lee JC: Nasopharyngeal carcinoma cell line (C666-1) consistently
harbouring Epstein-Barr virus. Int J Cancer 1999, 83(1):121–126.
28. Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson
BC, Milosevic M, Lo KW, et al: Imaging the modulation of adenoviral
kinetics and biodistribution for cancer gene therapy. Mol Ther 2007,
15(5):921–929.
29. Busson P, Ganem G, Flores P, Mugneret F, Clausse B, Caillou B, Braham K,
Wakasugi H, Lipinski M, Tursz T: Establishment and characterization of
three transplantable EBV-containing nasopharyngeal carcinomas.
Int J Cancer 1988, 42(4):599–606.
30. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA,
Nealon C, Dakic A, Simic V, et al: ROCK inhibitor and feeder cells induce
the conditional reprogramming of epithelial cells. Am J Pathol 2012,
180(2):599–607.
31. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M,
Narumiya S: Pharmacological properties of Y-27632, a specific inhibitor of
rho-associated kinases. Mol Pharmacol 2000, 57(5):976–983.
32. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS, Li YP: Two
epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with
Epstein-Barr virus that were derived from nasopharyngeal carcinomas.
Proc Natl Acad Sci USA 1989, 86(23):9524–9528.
33. Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM, Chuang SM, Wang
CC: Characterization of seven newly established nasopharyngeal
carcinoma cell lines. Lab Invest 1993, 68(6):716–727.
34. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG: A small
molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell
death. Science 2004, 305(5689):1471–1474.
35. Berenbaum MC: Criteria for analyzing interactions between biologically
active agents. Adv Cancer Res 1981, 35:269–335.
36. Friboulet L, Gourzones C, Tsao SW, Morel Y, Paturel C, Temam S, Uzan C,
Busson P: Poly(I:C) induces intense expression of c-IAP2 and cooperates
with an IAP inhibitor in induction of apoptosis in cancer cells.
BMC Cancer 2010, 10:327.
37. Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C,
Massacrier C, Conforti R, Chenard MP, Sabourin JC, et al: TLR3 as a
biomarker for the therapeutic efficacy of double-stranded RNA in breast
cancer. Cancer Res 2011, 71(5):1607–1614.
38. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T,
Kodama T, Fukayama M, Aburatani H: Identification of Toll-like receptor 3
as a potential therapeutic target in clear cell renal cell carcinoma.
Clin Cancer Res 2007, 13(19):5703–5709.
39. Chuang JH, Chuang HC, Huang CC, Wu CL, Du YY, Kung ML, Chen CH, Chen
SC, Tai MH: Differential toll-like receptor 3 (TLR3) expression and
apoptotic response to TLR3 agonist in human neuroblastoma cells.
J Biomed Sci 2011, 18:65.
40. Rydberg C, Mansson A, Uddman R, Riesbeck K, Cardell LO: Toll-like receptor
agonists induce inflammation and cell death in a model of head and
neck squamous cell carcinomas. Immunology 2009,
128(1 Suppl):e600–e611.41. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S,
Fujieda M, Kawa K, Takada K: Epstein-Barr virus (EBV)-encoded small RNA
is released from EBV-infected cells and activates signaling from Toll-like
receptor 3. J Exp Med 2009, 206(10):2091–2099.
42. Iwakiri D, Sheen TS, Chen JY, Huang DP, Takada K: Epstein-Barr virus-
encoded small RNA induces insulin-like growth factor 1 and supports
growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 2005,
24(10):1767–1773.
43. Takada K: Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC)
tumorigenesis. Semin Cancer Biol 2012, 22(2):162–165.
44. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D: mRNA is an
endogenous ligand for Toll-like receptor 3. J Biol Chem 2004,
279(13):12542–12550.
45. Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW,
Hogaboam CM, Kunkel SL: TLR3 is an endogenous sensor of tissue
necrosis during acute inflammatory events. J Exp Med 2008,
205(11):2609–2621.
46. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G:
Proapoptotic signalling through Toll-like receptor-3 involves TRIF-
dependent activation of caspase-8 and is under the control of inhibitor
of apoptosis proteins in melanoma cells. Cell Death Differ 2010,
17(6):942–951.
47. Matijevic T, Pavelic J: The dual role of TLR3 in metastatic cell line. Clin Exp
Metastasis 2011, 28(7):701–712.
48. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M,
Cain K, MacFarlane M, Hacker G, Leverkus M: cIAPs block Ripoptosome
formation, a RIP1/caspase-8 containing intracellular cell death complex
differentially regulated by cFLIP isoforms. Mol Cell 2011, 43(3):449–463.
49. Imre G, Larisch S, Rajalingam K: Ripoptosome: a novel IAP-regulated cell
death-signalling platform. J Mol Cell Biol 2011, 3(6):324–326.
50. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, Sarrazin D,
Contesso G, Viguier J: Adjuvant treatment with polyadenylic-polyuridylic
acid (Polya.Polyu) in operable breast cancer. Lancet 1980, 2(8187):161–164.
51. Lacour J, Laplanche A, Malafosse M, Gallot D, Julien M, Rotman N, Guivarc'h
M, Roullet-Audy JC, Lasser P, Hautefeuille P, et al: Polyadenylic-polyuridylic
acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year
follow-up analysis of a multicentric double blind randomized trial.
Eur J Surg Oncol 1992, 18(6):599–604.
52. Pawlicki M, Jonca M, Krzemieniecki K, Zuchowska-Vogelgesang B: Results of
adjuvant therapy with the preparation Poly-a Poly-u in patients with
malignant melanoma during a 10-year observation. Wiad Lek 1993,
46(23–24):912–914.
53. Laplanche A, Alzieu L, Delozier T, Berlie J, Veyret C, Fargeot P, Luboinski M,
Lacour J: Polyadenylic-polyuridylic acid plus locoregional radiotherapy
versus chemotherapy with CMF in operable breast cancer: a 14 year
follow-up analysis of a randomized trial of the Federation Nationale des
Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res Treat
2000, 64(2):189–191.
54. Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, Min JS, Kim BS,
Chung HC: Phase III trial of adjuvant 5-fluorouracil and adriamycin versus
5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U)
for locally advanced gastric cancer after curative surgery: final results of
15-year follow-up. Ann Oncol 2008, 19(3):520–526.
55. Umemura N, Zhu J, Mburu YK, Forero A, Hsieh PN, Muthuswamy R, Kalinski
P, Ferris RL, Sarkar SN: Defective NF-kappaB signaling in metastatic head
and neck cancer cells leads to enhanced apoptosis by double-stranded
RNA. Cancer Res 2012, 72(1):45–55.
doi:10.1186/1750-9378-7-36
Cite this article as: Vérillaud et al.: Toll-like receptor 3 in Epstein-Barr
virus-associated nasopharyngeal carcinomas: consistent expression and
cytotoxic effects of its synthetic ligand poly(A:U) combined to a
Smac-mimetic. Infectious Agents and Cancer 2012 7:36.
